Omar Nesheiwat, MD
Epilepsy · Thousand Oaks, CANPI 1730683350
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by AbbVie at 41.9% of the total. 2025 is the largest year on record at $5,924, 3.8 times the $1,568 reported in 2022.
Across 203 payments — averaging $50.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Neuropace, Inc.$1K
- UCB, Inc.$923
- Neurelis, Inc.$853
- Pfizer$461
- Acadia Pharmaceuticals Inc$411
- plus $2K from 17 others
What the payments were for
- Consulting fees$3,30032%
- Travel & lodging$1,24912%
- Food & beverage$5,79356%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $4,330 |
| Neuropace, Inc. | 3 | $1,428 |
| UCB, Inc. | 21 | $923 |
| Neurelis, Inc. | 34 | $853 |
| Pfizer | 32 | $461 |
| Acadia Pharmaceuticals Inc | 14 | $411 |
| SK Life Science, Inc. | 12 | $383 |
| Merz Pharmaceuticals, LLC | 8 | $268 |
| Penumbra, Inc. | 2 | $240 |
| Eisai Inc. | 8 | $163 |
| Jazz Pharmaceuticals Inc. | 2 | $143 |
| Xtant Medical Inc | 1 | $121 |
| Vanda Pharmaceuticals Inc. | 4 | $100 |
| Lilly USA, LLC | 4 | $92 |
| AstraZeneca | 5 | $87 |
| Teva Pharmaceuticals USA, Inc. | 3 | $85 |
| Grifols USA, LLC | 4 | $85 |
| Microtransponder, Inc. | 2 | $58 |
| Neurocrine Biosciences, Inc. | 1 | $36 |
| Johnson & Johnson | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Forte Bio-pharma LLC | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$3,548
- RNS Neurostimulator Kit$1,428
- Penumbra System$240
- VALTOCO$146
How this compares
$10,341 in reported general payments places this provider in the 80th percentile of 46 epilepsy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BetaseronInterferon Beta-1b | 12 | $117,102 |
| NuplazidPimavanserin Tartrate | 12 | $59,397 |
| BriviactBrivaracetam | 24 | $38,569 |
| XcopriCenobamate | 20 | $24,378 |
| Lacosamide | 48 | $17,444 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $9,490 |
| RytaryCarbidopa/Levodopa | 16 | $7,705 |
| Rivastigmine | 21 | $7,177 |
| Gabapentin | 237 | $5,949 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 57 | $4,725 |
| Pregabalin | 116 | $4,708 |
| Donepezil Hcl | 199 | $4,245 |
| Duloxetine Hcl | 98 | $3,057 |
| Lisdexamfetamine Dimesylate | 13 | $2,775 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 62 | $2,730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $411 | $59,39712 claims |
| UCB, Inc.Briviact | $923 | $38,56924 claims |
| SK Life Science, Inc.Xcopri | $383 | $24,37820 claims |
| Lilly USA, LLCOlanzapine | $92 | $50725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 46 epilepsy providers in California.
Other epilepsy in Thousand Oaks
- David King StephensOrange$551K
- Josef ParviziStanford$438K
- Mona SazgarOrange$222K
- Kimford MeadorStanford$50K
- Robert FisherStanford$41K
- Martha MorrellStanford$17K
- George NuneArcadia$13K
- Joshua LoebLoma Linda$7K
- Taha GholipourSan Diego$7K
- Kurt QingOrange$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.